Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New Seroquel data show significant improvement in compliance and cognition in schizophrenia

24.05.2005


Patients with schizophrenia who are treated with the atypical antipsychotic SEROQUEL (Quetiapine) show significantly superior rates of treatment compliance compared to patients treated with other atypical and typical antipsychotics, according to new data presented today at the American Psychiatry Association (APA) meeting in Atlanta, USA. Additional data presented today also showed improved cognitive functioning for patients with schizophrenia who are treated with SEROQUEL.



The compliance study is one of the few to compare both atypical antipsychotics with each other as well as with typical antipsychotics in schizophrenia. The findings show SEROQUEL to have the highest compliance rate of both typicals and atypicals, which was significantly (P<0.05) greater than that of risperidone (6% greater) and olanzapine (4% greater). These are welcome results in a patient environment where up to 50% of patients fail to comply with their prescribed medication, leading to an increased risk of relapse. This can result in the need for rehospitalisation and potential for high socioeconomic costs.

"Compliance with medication is fundamental to a successful treatment outcome in schizophrenia. However, all too often patients have to struggle with medications that cause distressing side effects such as extrapyramidal symptoms (EPS), increased prolactin levels leading to galactorroeha and sexual dysfunction, which makes complying with treatment a challenge many patients find too difficult to overcome" commented Dr Michael Riedel from the Munich University Hospital, Germany. "It is critical therefore that medications are not only effective in treating symptoms but are also well tolerated, which is where atypicals such as SEROQUEL are able to offer patients an improved outcome."


Cognitive Function

Two other studies presented at this year’s APA meeting compared the cognitive benefits of SEROQUEL and risperidone in patients with schizophrenia, demonstrating improvements in cognitive function among Seroquel-treated patients:

  • In a randomized, double-blind study of 44 patients, both SEROQUEL and risperidone improved cognition in patients with schizophrenia over a 6-week period. However, SEROQUEL (at a mean dose of 566.7 mg/day) produced significantly greater improvements in working and verbal memory than risperidone (p<0.01 and p<0.05 vs risperidone, respectively), with a significantly lower incidence of EPS, a highly distressing treatment-induced side effect
  • In an 8-week, double-blind, flexible-dose, parallel study randomizing 673 patients with schizophrenia, cognitive benefits of SEROQUEL (mean modal dose of 530 mg/day) and risperidone were compared. Both medications were associated with overall improvements in cognitive functioning (p<0.01) versus baseline.

"It is encouraging to see that SEROQUEL appears to be at least as effective as risperidone in improving cognitive function while also demonstrating a superior side effect profile in terms of extrapyramidal symptoms" continued Dr. Riedel. "Cognitive impairment is a serious symptom but one which is sometimes perceived as less important than some other symptoms of schizophrenia, such as hallucinations. However, recent studies have found that cognitive function is directly related to many areas of social interaction, and can limit an individual from being able to benefit fully from rehabilitation programmes. That is why treating these symptoms effectively is so important."

SEROQUEL has been licensed for the treatment of schizophrenia since 1997 and is available in 82 countries for the treatment of this condition. Results of recent studies show that 600mg/day is an efficacious SEROQUEL dose in patients with schizophrenia. SEROQUEL is also licensed in 63 countries for the treatment of mania associated with bipolar disorder, including the US, Canada and several European countries. To date, over 8 million people have been treated with SEROQUEL worldwide.

Sarah Fraser | EurekAlert!
Further information:
http://www.shirehealth.com

More articles from Health and Medicine:

nachricht When the eyes move, the eardrums move, too
24.01.2018 | Duke University

nachricht Deaf children learn words faster than hearing children
24.01.2018 | Max-Planck-Institut für Kognitions- und Neurowissenschaften

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Optical Nanoscope Allows Imaging of Quantum Dots

Physicists have developed a technique based on optical microscopy that can be used to create images of atoms on the nanoscale. In particular, the new method allows the imaging of quantum dots in a semiconductor chip. Together with colleagues from the University of Bochum, scientists from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute reported the findings in the journal Nature Photonics.

Microscopes allow us to see structures that are otherwise invisible to the human eye. However, conventional optical microscopes cannot be used to image...

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Physicists have learned to change the wavelength of Tamm plasmons

24.01.2018 | Physics and Astronomy

When the eyes move, the eardrums move, too

24.01.2018 | Health and Medicine

Deaf children learn words faster than hearing children

24.01.2018 | Health and Medicine

VideoLinks Science & Research
Overview of more VideoLinks >>>